BioMarin Pharmaceuticals (BMRN) Stock: Buy, Sell, or Hold?
BMRN - BioMarin Pharmaceuticals Inc
$57.18
-1.26 (-2.16%)
▼
5d:
-5.11%
30d:
-14.62%
90d:
-2.74%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 26, 2026
21d
Get Alerted When BMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BMRN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BMRN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$122.47
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$76.04
24.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMRN is currently trading at $57.18, which is considered oversold relative to its 30-day fair value range of $61.09 to $66.35. The stock's valuation (Forward PE: 8.6) is in line with its historical norms (9.5). Remarkably, the market is currently pricing in an annual earnings decline of 3.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BMRN is in a strong uptrend. The price is currently testing key support at $57.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BMRN scores 22/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $91.62 (+60.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BMRN is in a strong uptrend. The price is currently testing key support at $57.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BMRN scores 22/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $91.62 (+60.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$61.09 -
$66.35
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding BMRN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (22/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 60.2% below Wall St target ($91.62)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$61.09 -
$66.35
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$57.15
Resistance Level
$64.96
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.64
Wall Street Target
$91.62
(+60.2%)
Revenue Growth (YoY)
19.9%
Earnings Growth (YoY)
-81.3%
Profit Margin
2.1%
Valuation Discount vs History
-3.1% cheaper
PE vs Historical
8.6 vs 9.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.1%
(market-implied from PE analysis)
1-Year Target
$55.41
(-3%)
2-Year Target
$53.69
(-6%)
3-Year Target
$52.03
(-9%)
3-Yr Target (if PE normalizes)
(PE: 9→10)
$57.22
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 34.0%)
$324.72
(+468%)
Base:
(SPY PE: 8.6, Growth: 34.0%)
$137.49
(+141%)
Bear:
(PE: 7.3, Growth: 34.0%)
$116.87
(+104%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (9x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Forward PE: 9.40 | Forward EPS (Implied): $6.08
Bull Case
$69.04
(+21%)
Analyst growth 15.0%, PE expands to 9.9
Base Case
$57.18
(0%)
Market implied 0.0%, PE stable at 9.4
Bear Case
$43.74
(-24%)
Severe decline -15.0%, PE contracts to 8.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.6 to 9.5
Stabilization Target:
$62.89
(+10.0%)
PE Expansion Potential:
+10.0%
Share & Embed Analysis
Last updated: October 03, 2026 9:06 PM ET
Data refreshes hourly during market hours. Next update: 10:06 PM
Data refreshes hourly during market hours. Next update: 10:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |
Advanced BMRN Option Strategies
Professional options setups generated by AI based on today's BMRN price and gamma walls.
